Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Washington D.C, U.S.A——23rd March，Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”) obtained FDA（Food and Drug Administration）approval in U.S.A for its in-house developed PathBuilder™ Transseptal Guiding Introducer and Transseptal Needle.
Arrhythmia is a common disease of cardiovascular diseases, and RF ablation is an important treatment for arrhythmia. The PathBuilder™ is specially indicated for the RF ablation of cardiac arrhythmias. It is used to enter the femoral vein and establish a vascular access, and guide the diagnostic catheter or ablation catheter to enter each cardiac chamber，assist catheter to target position and provide support.
Previously，the PathBuilder™ Steerable Introducer independently developed by MicroPort EP has already been approved by FDA. The FDA approval of PathBuilder™ Transseptal Guiding Introducer and Transseptal Needle marks the complete set of intra cardiac guidance access of MicroPort EP has stepped into the US market.
In the future, MicroPort EP will continue to build a differentiated product portfolio and expand its global reach, offering comprehensive solutions for diagnosis and therapy of EP interventions for doctors and patients worldwide.
